The European Institute For Innovation Thr~ugh Health Data (i~HD) will launch at its inaugural conference on March 10, 2016 in Paris. The conference will present the IMI EHR4CR platform for connecting securely to clinical data across Europe to help plan clinical trials. i~HD aims to accelerate development of innovative medicines by improving quality and sharing of health data while respecting patient privacy. Major pharmaceutical companies and patient advocacy groups are invited to learn about using the EHR4CR platform to enhance treatment options through more efficient clinical research.

1. The European Institute For
Innovation Thr~ugh Health Data
Inaugural conference
March 10th 2016
At this conference on March 10 in Paris, we will launch i~HD, a European institute with a mission to guide and catalyse the
quality, interoperability and trustworthy uses of health data, for optimising health and knowledge discovery.
It will mark the continuity of the Electronic Health Records for Clinical Research (EHR4CR) project which has developed a platform
and services to re-use Electronic Health Record (EHR) data for multi-centre clinical research. This web-based platform can connect
securely to the data within multiple hospital and clinical data warehouses across Europe, to enable a trial sponsor to predict the
number of eligible patients for a candidate clinical trial protocol, better target the population to treat; and to locate the most
relevant hospital sites to perform the trial. Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, GSK, Janssen, Roche, Sanofi, and
ICON, who are all attending the conference, will begin using the Custodix-developed platform during 2016.
The deep aim of this initiative is to provide patients with faster access to safe and effective medicines, improving health outcomes
across Europe.This will be feasible by accelerating the development and achieving best practice that is patient-centered, leveraging
personalized medicine for better patient care and a more inclusive route to inclusion in clinical trials. Eventually, it will lead to
enhanced treatment options, giving patients faster access to innovative medicines and more personalised care pathways.
i~HD is an outcome and sustainability of projects from the European Innovative Medicines Initiative (IMI) and the European
Commission’s Seventh Framework Programme. It will enable, coordinate, and accelerate the efficient development and
deployment of interoperable and seamless eHealth solutions and research strategies, towards achieving best practices and
sustainable integrated person-centered health care, to optimize health and wellness in Europe, and beyond.
This inaugural conference will present the IMI EHR4CR platform and its adoption programme for 2016. It will also spotlight the
challenges and state-of-the-art approaches to improving the quality and semantic interoperability of clinical data. The conference
will include patient’s perspective on the benefits of reusing their data for research presented by Mary Baker, former President of the
European Brain Council, one of the keynote speakers.
The conference will take place at University Paris 6, Campus Les Cordeliers in Paris and is open to healthcare providers from across
Europe, to EFPIA members, patient associations, health professional associations, the health ICT industry, and standards bodies.
They are invited to register at http://www.i-hd.eu/IC2016/register.cfm.
The event is being organized by i-HD in collaboration with AP-HP, EuroRec, RAMIT and Sanofi.
About i~HD
The European Institute for Innovation through Health Data (i~HD) has been formed as one of the key sustainable entities arising
from the Electronic Health Records for Clinical Research (EHR4CR) and SemanticHealthNet projects, in collaboration with several
other European projects and initiatives supported by the European Commission.
About the IMI
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better
and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic
experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the
pharmaceutical industry association EFPIA.
The Institute is registered in Belgium as a not-for-profit organisation http://www.i-HD.eu